Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction

mAbs

Volumn 6, Issue 6, 2014, Pages 1560-1570

  Huet, Heather A ^a   Growney, Joseph D ^a   Johnson, Jennifer A ^a   Li, Jing ^a,d   Bilic, Sanela ^b   Ostrom, Lance ^b   Zafari, Mohammad ^a,e   Kowal, Colleen ^a   Yang, Guizhi ^a   Royo, Axelle ^b   Jensen, Michael ^b   Dombrecht, Bruno ^c   Meerschaert, Kris R A ^c   Kolkman, Joost A ^c,f   Cromie, Karen D ^c   Mosher, Rebecca ^b   Gao, Hui ^a   Schuller, Alwin ^a,g   Isaacs, Randi ^b   Sellers, William R ^a   Ettenberg, Seth A ^a   more..

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ABLYNX NV   (Belgium)

^d WUXI APPTEC   (China)

^e Jounce Therapeutics   (United States)

^f CRUCELL HOLLAND BV   (Netherlands)

^g ASTRAZENECA   (United Kingdom)

Author keywords

Apoptosis; Caspase; Death receptor; DR5; Nanobody; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CASPASE 3; CASPASE 8; CYTOKINE RECEPTOR AGONIST; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR 5; DEATH RECEPTOR 5 AGONIST; DEATH RECEPTOR 5 NB1 TETRA; NANOBODY; TETRAMER; UNCLASSIFIED DRUG; IL2RG PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR GAMMA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL LINE; CANCER PATIENT; CELL DEATH; CELL KILLING; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MOLECULAR CLONING; MOLECULAR WEIGHT; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN TARGETING; SURFACE PLASMON RESONANCE; TUMOR CELL; TUMOR MODEL; TUMOR REGRESSION; WESTERN BLOTTING; AGONISTS; ANIMAL; ANTIBODY AFFINITY; BIOSYNTHESIS; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; DEFICIENCY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENETICS; HCT116 CELL LINE; IMMUNOLOGY; KNOCKOUT MOUSE; NEOPLASMS; NONOBESE DIABETIC MOUSE; NUDE MOUSE; PROTEIN MULTIMERIZATION; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODY AFFINITY; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; HCT116 CELLS; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, NUDE; MICE, SCID; NEOPLASMS; PROTEIN MULTIMERIZATION; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SINGLE-DOMAIN ANTIBODIES; SURFACE PLASMON RESONANCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920821881     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/19420862.2014.975099     Document Type: Article

References (29)

1. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2LTRAIL. Oncogene 2010; 29:4752-65; PMID:20531300; http://dx.doi.org/ 10.1038onc.2010.221
2. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 2010; 16:1701-8; PMID:20197482; http://dx.doi.org/ 10.11581078-0432.CCR-09-1692
3. Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang YC, Wong S, Hill JS, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 2010; 16:5883-91; PMID:20947515; http://dx.doi. org/10.11581078-0432.CCR-10-0631
4. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, TohnyaTM, LumBL, et al. Phase I dose-escalation study of recombinant human Apo2LTRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010; 28:2839-46; PMID:20458040; http:// dx.doi.org/10.1200JCO.2009.25.1991
5. Kantari C, Walczak H. Caspase-8 and bid: caught in the act between death receptors and mitochondria. Biochim Biophys Acta 2011; 1813:558-63; PMID:21295084; http://dx.doi.org/10.1016j.bbamcr.2011.01.026
6. Yang A, Wilson NS, Ashkenazi A. Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr Opin Cell Biol 2010; 22:837-44; PMID:22789540; http://dx.doi.org/10.1016j. ccr.2012.05.014
7. Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF, Ashkenazi A, de Vos AM. Triggering cell death: the crystal structure of Apo2LTRAIL in a complex with death receptor 5. Mol Cell 1999; 4:563-71; PMID:10549288;www.sciencedirect. comsciencearticlepiiS1097276500802075"
8. Mongkolsapaya J, Grimes JM, Chen N, Xu XN, Stuart DI, Jones EY, Screaton GR. Structure of the TRAILDR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol 1999; 6:1048-53; PMID:10542098; http://dx.doi.org/10.103814935
9. Chan FK. The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function. Ann Rheum Dis 2000; 59 Suppl 1: i50-3:i50-i53; PMID:11053089; www.ncbi.nlm.nih. govpmcarticlesPMC1766631"
10. Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, Lenardo MJ, Chan FK. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 2005; 102:18099-104; PMID:16319225; http:// dx.doi.org/10.1073pnas.0507329102
11. Pavet V, Beyrath J, Pardin C, Morizot A, Lechner MC, Briand JP, Wendland M, Maison W, Fournel S, Micheau O, et al. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity. Cancer Res 2010; 70:1101-10; PMID:20103630; http://dx.doi.org/10.11580008-5472.CAN-09-2889
12. Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M, et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 2008; 15:751-61; PMID:18219321; http://dx.doi.org/ 10.1038sj.cdd.4402306
13. Motoki K, Mori E, Matsumoto A, Thomas M, Tomura T, Humphreys R, Albert V, Muto M, Yoshida H, Aoki M, et al. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res 2005; 11:3126-35; PMID:15837769; http://dx.doi.org/10.11581078-0432.CCR-04-1867
14. Natoni A, MacFarlane M, Inoue S, Walewska R, Majid A, Knee D, Stover DR, Dyer MJ, Cohen GM. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br J Haematol 2007; 139:568-77; PMID:17922877; http://dx.doi.org/10.1111j.1365-2141.2007.06852.x
15. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, Li Y, Pitti R, Totpal K, Yee S, et al. An Fcgamma receptor-dependent mechanism drives anti-body-mediated target-receptor signaling in cancer cells. Cancer Cell 2011; 19:101-13; PMID:21251615; http://dx.doi.org/10.1016j.ccr.2010.11.012
16. Li F, Ravetch JV. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcgamma receptor engagement. Proc Natl Acad Sci USA 2012; 109:10966-71; PMID:22723355; http://dx.doi.org/ 10.1073pnas.1208698109
17. Van Bockstaele F, Holz JB, Revets H. The development of nanobodies for therapeutic applications. Curr Opin Investig Drugs 2009; 10:1212-24; PMID:19876789; http:europepmc.orgabstractMED19876789reload=0; jsessionid=oaDbUtiWgC0MR8?5rVM6.12
18. Sharma S, de Vries EG, Infante JR, Oldenhuis CN, Gietema JA, Yang L, Bilic S, Parker K, Goldbrunner M, Scott JW, et al. Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs 2013; 32:135-44; PMID:23589214; http://dx.doi.org/ 10.1007s10637-013-9952-9
19. Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 2004; 5:501-12; PMID:15144957; http://dx.doi. org/10.1016S1535-6108(04)00113-8
20. Strachan DC, Ruffell B, Oei Y, Bissell MJ, Coussens LM, Pryer N, Daniel D. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells. Oncoimmunology 2013; 2:e26968; PMID:24498562; http://dx.doi.org/10.11771091581811401920
21. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Cora D, Di NF, Buscarino M, Petti C, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011; 1:508-23; PMID:22586653; http://dx.doi.org/10.11582159-8290.CD-11-0109
22. Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 2013; 5:171ra17; PMID:23390247; http://dx.doi.org/ 10.1126scitranslmed.3004828
23. Wang G, Wang X, Yu H, Wei S, Williams N, Holmes DL, Halfmann R, Naidoo J, Wang L, Li L, et al. Smallmolecule activation of the TRAIL receptor DR5 in human cancer cells. Nat Chem Biol 2013; 9:84-9; PMID:23292651; http://dx.doi.org/10.1038nchembio. 1153
24. Gieffers C, Kluge M, Merz C, Sykora J, Thiemann M, Schaal R, Fischer C, Branschadel M, Abhari BA, Hohenberger P, et al. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcgamma receptors. Mol Cancer Ther 2013; 12:2735-47; PMID:24101228; http://dx.doi.org/10.11581535-7163.MCT-13-0323
25. Ashkenazi A, Holland P, Eckhardt SG. Ligandbased targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2LTRAIL). J Clin Oncol 2008; 26:3621-30; PMID:18640940; http://dx.doi.org/10.1200JCO. 2007.15.7198
26. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA. Preclinical studies to predict the disposition of Apo2Ltumor necrosis factor-related apopto-sis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299:31-8; PMID:11561060; http:// jpet.aspetjournals.org/content/299/1/31.long
27. Wilson NS, Yang A, Yang B, Couto S, Stern H, Gogineni A, Pitti R, Marsters S, Weimer RM, Singh M, et al. Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth. Cancer Cell 2012; 22:80-90; PMID:22789540; http://dx.doi.org/10.1016j. ccr.2012.05.014
28. Vosjan MJ, Vercammen J, Kolkman JA, Stigter-van WM, Revets H, van Dongen GA. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther 2012; 11:1017-25; PMID:22319202; http://dx.doi. org/10.11581535-7163.MCT-11-0891
29. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de CP, de PL, Guyader C, de PG, Judde JG, et al. A new model of patient tumorderived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007; 13:3989-98; PMID:17606733; http://dx.doi.org/10.11581078-0432.CCR-07-0078